Replies to post #93812 on Innovation Pharmaceuticals Inc (IPIX)

[Drano]

As someone just pointed out here this afternoon, the "skin products" are a different category. That is another arrow in the quiver. I don't think that something has to actually be in human trials yet to be counted; by that standard, most developmental stage biotechs would be said to have no arrows in their quiver.

CTIX has cancer arrows; infection arrows; psoriasis arrows. Arrows still to have arrowheads affixed: autism, and who knows what-all else.

And most small biotechs are lucky to have one drug, in one category, in human trials. CTIX will have 3, and more trials expected this year. I think that's getting close to a quiver-full.

[Astavakra]

No, it's not a given in the sense that you can sit and logically draw a conclusion. It would actually take some research to understand the possibilities of the protein mimetics; then you could draw a more considered conclusion. I have done a bit of that research, but you'll have to do your own. Giving it away for nothing apparently decreases its value.

[frrol]

My background isn't biochem. I assumed that if Brilacidin wouldn't worry on a particular bug, something in the defensin mimetic platform would, due to the common MOA. From your post, this is not a safe assumption I guess.